Dynavax Technologies Corp. (DVAX)

16.15
NASDAQ : Health Technology
Prev Close 15.90
Day Low/High 15.72 / 16.20
52 Wk Low/High 7.55 / 24.45
Avg Volume 1.69M
Exchange NASDAQ
Shares Outstanding 62.27M
Market Cap 990.16M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

These names are moving up or down in a big way ahead of releasing drug-trial results.

4 Names to Watch Ahead of Cancer Conference

4 Names to Watch Ahead of Cancer Conference

American Society of Clinical Oncology will see presentations from dozens of companies.

4 Names to Buy in a Refreshed Biotech Space

4 Names to Buy in a Refreshed Biotech Space

After a strong week for the biotech sector, these names have potential catalysts to move shares.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

3 Favorite Biotech Stocks for the Second Quarter

3 Favorite Biotech Stocks for the Second Quarter

Your questions are answered in our latest addition of the biotech mailbag.

Interesting DVAX Put And Call Options For May 18th

Interesting DVAX Put And Call Options For May 18th

Investors in Dynavax Technologies Corp saw new options become available this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DVAX options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

Twilio, Apache, Tellurian: 'Mad Money' Lightning Round

Twilio, Apache, Tellurian: 'Mad Money' Lightning Round

Jim Cramer spotlights Twilio, Apache, Tellurian, Atara Biotherapeutics, Amarin, Dynavax Technologies

This Bull Still Runs: Cramer's 'Mad Money' Recap (Friday 3/9/18)

This Bull Still Runs: Cramer's 'Mad Money' Recap (Friday 3/9/18)

Jim Cramer says this is a market that triumphs over the gloom by simply taking stock of the good and running with it. He's got your game plan for next week.

Noteworthy Thursday Option Activity: DVAX, LVS, CVNA

Noteworthy Thursday Option Activity: DVAX, LVS, CVNA

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Dynavax Technologies Corp , where a total volume of 8,938 contracts has been traded thus far today, a contract volume which is representative of approximately 893,800 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 76.2% of DVAX's average daily trading volume over the past month, of 1.2 million shares.

Stanley A. Plotkin, M.D. Steps Down From Board Of Dynavax Technologies

Stanley A. Plotkin, M.D. Steps Down From Board Of Dynavax Technologies

Dr. Plotkin Will Continue as Scientific Advisor

First Week of October 19th Options Trading For Dynavax Technologies (DVAX)

First Week of October 19th Options Trading For Dynavax Technologies (DVAX)

Investors in Dynavax Technologies Corp saw new options become available this week, for the October 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Dynavax's HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended By CDC Advisory Committee On Immunization Practices For The Prevention Of Hepatitis B In Adults

Dynavax's HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended By CDC Advisory Committee On Immunization Practices For The Prevention Of Hepatitis B In Adults

HEPLISAV-B is the First and Only Two-Dose Vaccine in the U.S. for Hepatitis B Prevention in Adults

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Dynavax Announces HEPLISAV-B™ Is Now Available In The United States For The Prevention Of Hepatitis B In Adults

Dynavax Announces HEPLISAV-B™ Is Now Available In The United States For The Prevention Of Hepatitis B In Adults

HEPLISAV-B is the First and Only Two-Dose Vaccine in U.S. for Hepatitis B Prevention in Adults

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

Acadia, Dynavax Make the Biotech Mailbag

Acadia, Dynavax Make the Biotech Mailbag

Readers have asked about Acadia Pharmaceuticals and Dynavax Technologies, so we answer.

TheStreet Quant Rating: D- (Sell)